Abstract Purpose Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly (ADP-
ribose) polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of …

The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on
cardiac repolarization in patients with advanced solid tumors by assessing corrected QT …

Abstract Effects of therapeutic and supratherapeutic concentrations of bosutinib, a dual
Src/Abl tyrosine kinase inhibitor, on the corrected QT interval (QTc) in 60 healthy adults were …

Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few
treatment options. Rovalpituzumab tesirine (Rova‐T) is an antibody‐drug conjugate that …

Purpose The aim of this analysis was to investigate the potential for ulixertinib (BVD-523) to
prolong cardiac repolarization. The mean prolongation of the corrected QT (QTc) interval …

Purpose Linifanib is a selective inhibitor of the vascular endothelial growth factor and
platelet-derived growth factor family of tyrosine kinase inhibitors. The purpose of this high …

Purpose QT assessment of oncology drugs is generally challenging because they are
genotoxic and, of necessity, they require multisite evaluation in cancer patients. Lenvatinib is …

Purpose Anticancer drugs may cause cardiovascular toxicities, including QT interval
prolongation. Niraparib, a potent and selective once-daily oral poly (ADP-ribose) …

Purpose Trametinib is a reversible, selective inhibitor of the mitogen-activated extracellular
signal-regulated kinase 1 (MEK1) and 2 (MEK2). Cardiotoxicity (congestive heart failure …

Purpose To characterize the effect of erdafitinib on electrocardiogram (ECG) parameters and
the relationship between erdafitinib plasma concentrations and QTc interval changes in …